Short answer
Foghorn Therapeutics Inc. (FHTX) filed an 8-K current report with the SEC on May 7, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Q1 2026 financial results for quarter ended March 31, 2026.
Foghorn Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results for quarter ended March 31, 2026
- Press release issued May 7, 2026
- Detailed financial figures available in Exhibit 99.1
Item 7.01 · Regulation FD Disclosure
- Investor presentation dated May 2026 furnished as Exhibit 99.2 under Regulation FD
- Materials intended for investor meetings, potentially containing updated business or pipeline information
- Exhibit 99.2 is the primary source for evaluating market-relevant disclosures
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Foghorn Therapeutics Inc. 8-K filings
Get the next FHTX 8-K as it lands
Follow FHTX for push alerts, or ask the research agent what this filing means.